Actio Biosciences
PrivateLast Round
Series B
Jun 18, 2025
Total Funding Raised
$137M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Actio Biosciences is a biotechnology company that develops precision medicines targeting the underlying genetic biology of rare diseases with potential applications for more prevalent indications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Actio Biosciences Comparables
Compare Actio Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GRIN Therapeutics, Inc. | 80% | |
| IAMA Therapeutics | 79% | |
| Praxis Precision Medicines, Inc. | 79% |
Actio Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 18, 2025 | ||||
| Series A | Sep 12, 2023 | ||||
| Seed | May 1, 2022 | ||||
| Seed | Oct 1, 2021 |
Key People
Founding team and executive leadership
Actio Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Seed, Series A |
| Deerfield Management | Seed, Series A, Series B |
| Droia Ventures | Series A, Series B |
| Canaan Partners | Series B, Series A |
| Euclidean Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 140% MoM.
- Aug 28, 2026
Grew 23% QoQ, from 40 to 49 employees.
Recent news
Latest coverage and updates
- is_developingAug 11, 2026
Actio Biosciences, Inc. is testing ABS-1230 in the Phase 1b/2a KYRON study, which is intended to support a potential regulatory filing in the United States.
- receives_financingAug 10, 2026
On Aug 10th '26, Actio Biosciences, Inc. receives $1.3B from Jazz Pharmaceuticals to strengthen epilepsy treatment development.
Actio Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Actio Biosciences's valuation, stock price, and market status.
Is Actio Biosciences a public or private company?
Actio Biosciences is a private company.
What is the current stock price of Actio Biosciences?
Actio Biosciences is a private company, so its shares have no public market price. Caplight tracks Actio Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Actio Biosciences worth (valuation)?
Valuation information for Actio Biosciences is not publicly available.
Can I buy Actio Biosciences stock?
Actio Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Actio Biosciences's last funding round?
Actio Biosciences's most recent funding round was Series B on June 18, 2025.
Who are the main investors in Actio Biosciences?
Key investors in Actio Biosciences include Deerfield Management, Droia Ventures, Canaan Partners.
Will Actio Biosciences IPO soon?
No public IPO plans have been announced for Actio Biosciences.
How can I track Actio Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Actio Biosciences's shares on secondary markets.